We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

178 hedge funds and large institutions have $2.13B invested in Intra-Cellular Therapies Inc. in 2020 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 60 increasing their positions, 51 reducing their positions, and 38 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

41% more call options, than puts

Call options by funds: $30.1M | Put options by funds: $21.3M

35% more capital invested

Capital invested by funds: $1.58B → $2.13B (+$548M)

18% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 51

1% more funds holding

Funds holding: 176 → 178 (+2)

8% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 38

Holders
178
Holders Change
+2
Holders Change %
+1.14%
% of All Funds
3.15%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
41
Increased
60
Reduced
51
Closed
38
Calls
$30.1M
Puts
$21.3M
Net Calls
+$8.78M
Net Calls Change
+$314K

Top Buyers

Rank Fund Capital Flow
1
WA
Wasatch Advisors
Utah
+$24.3M
2
BlackRock
BlackRock
New York
+$16.5M
3
Goldman Sachs
Goldman Sachs
New York
+$12M
4
SCM
Suvretta Capital Management
New York
+$10.9M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$9.52M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$14.3M
2
Millennium Management
Millennium Management
New York
-$10.6M
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$9.73M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$8.88M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$7.41M
Name Holding Trade Value Shares
Change 		Change in
Stake
Rafferty Asset Management
126
Rafferty Asset Management
New York
$371K +$307K +11,666 New
Handelsbanken Fonder
127
Handelsbanken Fonder
Sweden
$363K – – –
MPCG
128
Matrix Private Capital Group
New York
$359K -$13.1K -500 -4%
WAM
129
Wolverine Asset Management
Illinois
$356K +$295K +11,222 New
VHAM
130
Van Hulzen Asset Management
California
$350K +$5.26K +200 +2%
M&T Bank
131
M&T Bank
New York
$348K -$242K -9,223 -46%
Natixis Advisors
132
Natixis Advisors
Massachusetts
$342K +$283K +10,758 New
Squarepoint
133
Squarepoint
New York
$341K -$887K -33,746 -76%
YIH
134
Y-Intercept (HK)
Hong Kong
$337K +$275K +10,453 New
PCH
135
Polar Capital Holdings
United Kingdom
$336K +$277K +10,558 New
HF
136
HRT Financial
New York
$335K +$277K +10,545 New
Public Employees Retirement Association of Colorado
137
Public Employees Retirement Association of Colorado
Colorado
$329K – – –
Walleye Trading
138
Walleye Trading
New York
$326K +$187K +7,120 +227%
MML Investors Services
139
MML Investors Services
Massachusetts
$304K +$252K +9,570 New
Zurich Cantonal Bank
140
Zurich Cantonal Bank
Switzerland
$296K +$45.8K +1,741 +23%
HSBC Holdings
141
HSBC Holdings
United Kingdom
$290K +$239K +9,088 New
Los Angeles Capital Management
142
Los Angeles Capital Management
California
$290K +$240K +9,132 New
Nisa Investment Advisors
143
Nisa Investment Advisors
Missouri
$277K +$32.2K +1,225 +16%
ACM
144
AlphaCrest Capital Management
New York
$264K +$218K +8,300 New
MSL
145
Mackay Shields LLC
New York
$261K +$216K +8,200 New
AA
146
AlphaCentric Advisors
Puerto Rico
$254K +$196K +7,450 +1,355%
AB
147
Amalgamated Bank
New York
$238K +$197K +7,496 New
JCM
148
JS Capital Management
New York
$232K +$192K +7,300 New
VRS
149
Virginia Retirement Systems
Virginia
$216K +$179K +6,800 New
NIM
150
NXG Investment Management
Texas
$203K +$167K +6,373 New
4 5
6
7 8

ITCI Hedge Fund Activity: Q4 2020 in Review

178 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q4 2020, worth a combined $2.13B — up 35% from $1.58B a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new ITCI positions and 38 closed out — a net gain of 3 holders — while 60 added to existing stakes and 51 trimmed.

The largest buyer was Wasatch Advisors, adding an estimated $24.3M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $14.3M sold.

  • 178 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q4 2020, up from 176 in Q3 2020.
  • Funds reported $2.13B of Intra-Cellular Therapies Inc. stock for Q4 2020, up 35% quarter-over-quarter.
  • 41 funds opened new Intra-Cellular Therapies Inc. positions in Q4 2020 and 38 closed out, a net change of +3 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q4 2020 was Wasatch Advisors, an estimated $24.3M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q4 2020 was Point72 Asset Management, an estimated $14.3M sold.

Based on aggregated 13F filings for Q4 2020.